Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 106; no. 4; pp. 1193 - 1197
Main Authors Fayon, Maxime, Martinez-Cingolani, Carolina, Abecassis, Audrey, Roders, Nathalie, Nelson, Elisabeth, Choisy, Caroline, Talbot, Alexis, Bensussan, Armand, Fermand, Jean-Paul, Arnulf, Bertrand, Bories, Jean-Christophe
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.04.2021
Ferrata Storti Foundation
Subjects
Letters to the Editor
Online AccessGet full text
ISSN0390-6078
1592-8721
1592-8721
DOI10.3324/haematol.2019.242453

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
Disclosures: AA has received funds from Servier. Some of the work described in this letter is covered by a patent (international patent application number PCT/EP2020/070057).
Contributions: MF, CM-C and JCB designed the study; MF and CM-C performed all the experiments; AB provided the anti-CD38 hybridoma; AA and NR contributed to the functional assay; EN and CC performed the mouse studies; AT, JPF and BA provided samples from patients with multiple myeloma; MF, CM-C and JCB interpreted the data, designed the figures, and drafted the manuscript.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2019.242453